Evidence map›Paper›PMID 41739228›Full record

ArticleArchives of gynecology and obstetrics2026

Effect of alpha-lipoic acid and myoinositol on endometrial inflammation in women with unexplained recurrent pregnancy loss.

Chiara Tersigni, Maria Elisabeth Street, Roberta Castellani, Fiorella Di Nicuolo, Marianna Onori, Cecilia Catellani, Greta Barbaro, Carlo Ticconi, Nicoletta Di Simone

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chiara TersigniFondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168, Rome, Italy. chiara.tersigni@policlinicogemelli.it.
Maria Elisabeth StreetDepartment of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43124, Parma, Italy.
Roberta CastellaniUniversità Cattolica del Sacro Cuore, L.go F.Vito 1, 00168, Rome, Italy.
Fiorella Di NicuoloIstituto Scientifico Internazionale Paolo VI, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168, Rome, Italy.
Marianna OnoriUniversità Cattolica del Sacro Cuore, L.go F.Vito 1, 00168, Rome, Italy.
Cecilia CatellaniDepartment of Mother and Child, Azienda USL-IRCCS, di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.
Greta BarbaroUniversità Cattolica del Sacro Cuore, L.go F.Vito 1, 00168, Rome, Italy.
Carlo TicconiDepartment of Surgical Sciences, Section of Gynecology and Obstetrics, University of Rome Tor Vergata, Via Cracovia 90, 00133, Rome, Italy.
Nicoletta Di SimoneDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to investigate the effect of oral administration of a combination of alpha- lipoic acid (ALA) and myo-inositol (Myo) on serum and endometrial inflammation of women with unexplained recurrent pregnancy loss (uRPL).

methodsSerum and endometrial levels of Nacht leucine-rich-repeat protein-3 (NLRP-3) and High Mobility Group Box 1 (HMGB-1) were analyzed by ELISA in women with unexplained Recurrent Pregnancy Loss (uRPL) (n = 31) and in control women who had had at least one uncomplicated pregnancy at term (n = 10) before and after daily oral administration of a commercial combination of ALA and Myo.

resultsuRPL women had higher serum levels (p < 0.01) and endometrial content (p < 0.0001) of HMGB-1 than controls while no difference was observed regarding NALP3. Oral administration of ALA and Myo for three months significantly decreased pre-treatment serum levels of NLRP-3 (p < 0.0001) and HMGB-1 (p < 0.0001), as well as endometrial content of NLRP-3 (p < 0.001) and HMGB-1 (p < 0.0001) in uRPL women, similar to those found in controls.

conclusionWomen with uRPL have increased systemic and endometrial inflammation than controls. Oral administration of ALA and Myo could modulate serum and endometrial levels of NLRP-3 and HMGB-1 in uRPL women.

Indexed as

Abortion, HabitualEndometritisEndometriumInositolThioctic AcidAdministration, OralAdultCase-Control StudiesDrug Therapy, CombinationFemaleHMGB1 ProteinHumansNLR Family, Pyrin Domain-Containing 3 ProteinPregnancyHMGB1 ProteinHMGB1 protein, humanInositolNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanThioctic AcidAlpha‐lipoic acidEndometriumHMGB1InflammasomeMyoinositolUnexplained recurrent pregnancy loss

Identifiers

PMID41739228
PMCPMC12935864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.